Iroko Pharmaceuticals

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Iroko Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 12 completed top decile by trial count

Iroko Pharmaceuticals: 12 sponsored US clinical trials, none currently recruiting.

Iroko Pharmaceuticals sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 7 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Other Acute Postoperative Pain, with 1 trials.

Top-decile sponsor footprint

Iroko Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 2

Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

NCT02633969
COMPLETED Phase 2

Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

NCT02424578
COMPLETED Phase 3

Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip

NCT01801735
COMPLETED Phase 3

Study of Meloxicam Capsules to Treat Osteoarthritis Pain

NCT01787188
COMPLETED Phase 3

Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

NCT01626118
COMPLETED Phase 3

Study of Indomethacin Capsules to Treat Pain Following Bunionectomy

NCT01543685
COMPLETED Phase 3

Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01510912
COMPLETED Phase 3

Study of Diclofenac Capsules to Treat Pain Following Bunionectomy

NCT01462435
COMPLETED Phase 3

Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01461369
COMPLETED Phase 2

Study of Naproxen Capsules to Treat Dental Pain

NCT01229228
COMPLETED Phase 2

Study of Diclofenac Capsules to Treat Dental Pain

NCT00985439
COMPLETED Phase 2

Phase 2 Study of Indomethacin Capsules to Treat Dental Pain

NCT00964431

Phase Distribution

PhaseTrial count
Phase 2 5
Phase 3 7

Therapeutic Areas

Other Acute Postoperative Pain 1

How the Iroko Pharmaceuticals archive is shaped

12 indexed studies, none listed as recruiting (0% open); 12 completed (100%).

Phase mix: 7 late (III/IV) vs 5 early (I/II) (balanced across stages).

Top condition: Other Acute Postoperative Pain (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Iroko Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Iroko Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Iroko PharmaceuticalsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Iroko Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Iroko Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Iroko Pharmaceuticals page

12 registered trials is a research-attention snapshot, not an endorsement of Iroko Pharmaceuticals or any single study.

  • None of Iroko Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Other Acute Postoperative Pain is the condition Iroko Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Other Acute Postoperative Pain trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Iroko Pharmaceuticals pipeline card: 12 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.